Microbot Medical Inc.

Microbot Medical Inc. is a medical device company dedicated to the research, design, and development of next-generation robotic endoluminal surgery devices. Headquartered in Hingham, Massachusetts, the company's mission is to deliver transformative interventional robotic solutions that prioritize patient care, empower providers, and enable access to advanced care anytime, anywhere.

The company's flagship product is the LIBERTY® Endovascular Robotic Surgical System, a fully disposable, single-use, and remotely operated robotic solution designed for various endovascular interventional procedures, including those in peripheral vascular, and potentially neurovascular spaces. The LIBERTY system aims to enhance precision, reduce radiation exposure for medical professionals, and broaden access to advanced care by offering a compact and cost-effective alternative to traditional capital equipment. Microbot Medical also holds intellectual property related to other micro-robotic technologies such as ViRob, TipCAT, CardioSert, and NovaCross.

Led by Chairman, President, and CEO Harel Gadot, Microbot Medical achieved a significant milestone with FDA 510(k) clearance for its LIBERTY® system in September 2025. Following this, the company initiated a limited market release in late 2025 and commenced a full market release in the U.S. in April 2026. Notable collaborations include partnerships with Corewell Health and Emory University for the development of the LIBERTY system and autonomous robotics, with Emory Healthcare successfully completing initial robotic peripheral endovascular procedures using LIBERTY in March 2026. The company maintains a robust intellectual property portfolio, with 42 issued patents and 23 pending applications worldwide.

Latest updates

Microbot Medical Appoints EMEA Sales Lead, Eyes $2.3B Peripheral Market

Event summary

  • Microbot Medical appointed Alon Tamir as Vice President of Sales for Europe, the Middle East, and Asia (EMEA).
  • The move follows successful Limited and Full Market Releases of the LIBERTY Endovascular Robotic System in the U.S.
  • The EMEA region represents a peripheral endovascular procedure market estimated at approximately 2.3 million procedures annually.
  • Microbot anticipates receiving CE mark approval by the end of 2026, enabling expansion into European markets.
  • The company plans to leverage FDA clearance to accelerate international expansion where possible.

The big picture

Microbot Medical's expansion into EMEA represents a significant strategic shift, aiming to capitalize on a market opportunity roughly equivalent to the U.S. This move underscores the growing adoption of robotic-assisted surgery and the increasing globalization of medical device companies. The success of this international push will hinge on navigating complex regulatory pathways and establishing a robust commercial infrastructure.

What we're watching

Regulatory Headwinds
The timing and outcome of the CE mark approval will be critical for Microbot's EMEA entry strategy, potentially impacting the speed of market penetration.
Execution Risk
Successfully translating the U.S. launch discipline to the EMEA region, given differing regulatory landscapes and market dynamics, will be a key indicator of long-term success.
Competitive Landscape
How Microbot Medical differentiates its LIBERTY system against existing endovascular solutions and emerging robotic competitors in the EMEA market will determine its market share.
CID: 3295